Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program

Ribociclib plus an aromatase inhibitor and ovarian function suppression is the preferred first-line option for pre-/perimenopausal women with hormone receptor-positive/human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer. We opened an italian managed access program...

Descripción completa

Detalles Bibliográficos
Autores principales: Staropoli, Nicoletta, Geuna, Elena, Rinaldi, Gaetana, Bisagni, Giancarlo, Scotti, Vieri, Faggioni, Giovanni, Vannini, Laura, Arcara, Carlo, Moretti, Gabriella, Gunnellini, Marco, Coltelli, Luigi, Verderame, Francesco, Livi, Lorenzo, Sanna, Giuseppina, Grasso, Donatella, Abbinante, Giulia, Ragni, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498176/
https://www.ncbi.nlm.nih.gov/pubmed/36135090
http://dx.doi.org/10.3390/curroncol29090521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498176/
https://www.ncbi.nlm.nih.gov/pubmed/36135090
http://dx.doi.org/10.3390/curroncol29090521

Ejemplares similares